Credo's Q2 Earnings and Sales Beat Estimates, Up Y/Y, Stock Gains

Credo Technology reported a blowout Q2 FY2026 with adjusted EPS of $0.67 (vs $0.07 prior year), beating consensus by 36.7%, and revenues of $268.0M, up 272.1% YoY driven by product sales of $261.3M (+278.3%) and IP license revenue of $6.7M (+127.6%). Non-GAAP gross profit was $181.4M with gross margin at 67.7% (up 410 bps), non-GAAP operating expenses $57.3M, and cash/short-term investments of $813.6M as of Nov. 1, 2025. Management guided Q3 revenue to $335–$345M and reiterated robust FY26 outlook (roughly 170% YoY growth, non-GAAP net margin ~45%) citing demand from large AI training/inference clusters and upcoming product scale-ups (ZeroFlap Optics, ALCs, OmniConnect), sending shares up ~18% pre-market.

Analysis

Market structure: Credo (CRDO) is a direct beneficiary of hyperscaler AI training/inference capex — Q2 product revenue +278% to $261m and Q3 guide $335–345m imply sustained hyperscaler demand and mid-single-digit sequential growth toward ~170% FY26 YoY. Suppliers of optical components, MACsec silicon and testing capacity will see order upsides; smaller peers without hyperscaler design wins face pricing pressure. Customer concentration (top four >10% each) amplifies upside when volumes ramp but also creates single-customer exposure risk to share shifts.

Risk assessment: Key tail risks are a single hyperscaler inventory correction, a major design loss, or execution shortfalls on ZeroFlap/ALC scale-up; any of these could wipe out >20–30% of revenue in a quarter given concentration. Near-term (days–weeks) volatility will track guidance cadence and hyperscaler commentary; medium-term (3–12 months) risk centers on product qualification and capacity; long-term (>12 months) hinges on sustainable margin mix and wins beyond current customers. Hidden dependency: gross-margin expansion to ~64–66% and projected non-GAAP net margin ~45% assumes product mix and pricing remain intact — a material deviation should be monitored via monthly shipment indicators.

Trade implications: Tactical: establish modest directional exposure tied to execution — consider a 2–3% long equity position sized with a 15–20% stop and target 50–80% upside over 6–12 months if Q3 revenue hits midpoint. Use options to finance risk: sell 8–12% OTM cash-secured puts for near-term exposure or buy 9–12 month call spreads to limit downside while keeping upside. Pair trade: long CRDO, short NVTS (or underperforming small-cap GaN/charger names) at a 1:0.4 notional to neutralize sector beta, given NVTS’ revenue contraction and CRDO’s stronger cash position ($813.6m).

Contrarian angles: Market reaction (CRDO +18% premarket, +138% 6‑mo) may underappreciate concentration and opex ramp (non-GAAP opex +50% FY26). Consensus may be overrating margin sustainability — a single large customer pricing negotiation or product delay could compress non-GAAP gross margin by >500bps. Historical parallels (optics/ASIC ramp cycles) show rapid multiple expansion can reverse on one missed quarter; therefore size positions conservatively and require two sequential quarters of revenue/M gross-margin beat before adding to conviction.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in CRDO (equity) within 1–4 weeks, hold 6–12 months; set tactical stop-loss at 15–20% below entry and take-profit trim at +50%, add more only after two consecutive quarters beating revenue and non-GAAP gross-margin guidance (Q3 and Q4 fiscal 2026).
• Sell cash-secured puts 8–12% OTM expiring 30–90 days to collect premium and acquire CRDO at a discount; size notional equal to intended equity allocation and roll if premium >1.5% of strike or if Q3 guide misses midpoint ($340m).
• Buy a 9–12 month bull call spread on CRDO to capture upside while capping cost (target payoff range 40–60% upside); size to replace 25–50% of the equity stake and close if non-GAAP gross margin drops below 64% or Q3 revenue < guidance lower bound ($335m).
• Execute a pair trade: go long CRDO and short NVTS sized 1:0.4 to neutralize semiconductor beta, initiating within 2 weeks; unwind if NVTS shows revenue recovery (sequential revenue increase >20%) or CRDO’s customer concentration reduces (new large customer announced).
• Reduce exposure by ~30% to small-cap, single-customer-dependent semiconductor names and redeploy 2–4% of portfolio into QCOM or diversified large-cap semiconductor names as defensive alpha — target holding 3–9 months while monitoring hyperscaler order commentary.